BR112018069504A2 - composto de sultam e método de aplicação do mesmo - Google Patents

composto de sultam e método de aplicação do mesmo

Info

Publication number
BR112018069504A2
BR112018069504A2 BR112018069504A BR112018069504A BR112018069504A2 BR 112018069504 A2 BR112018069504 A2 BR 112018069504A2 BR 112018069504 A BR112018069504 A BR 112018069504A BR 112018069504 A BR112018069504 A BR 112018069504A BR 112018069504 A2 BR112018069504 A2 BR 112018069504A2
Authority
BR
Brazil
Prior art keywords
compound
sultam
application
solvates
hydrates
Prior art date
Application number
BR112018069504A
Other languages
English (en)
Other versions
BR112018069504B1 (pt
Inventor
Zhang Hui
Zhu Li
Dai Liguang
Zhao Rui
Wang Shanchun
Duan Xiaowei
Tian Xin
Yang Yanqing
Peng Yong
Han Yongxin
Hu Yuandong
Yang Zhao
Original Assignee
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Centaurus Biopharma Co Ltd
Publication of BR112018069504A2 publication Critical patent/BR112018069504A2/pt
Publication of BR112018069504B1 publication Critical patent/BR112018069504B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

um composto de sultam que apresenta atividade inibitória de isocitrato desidrogenase 1 (idh1), conforme representado pela fórmula i, ou sais, solvatos ou hidratos farmaceuticamente aceitáveis do mesmo, um método de preparação do mesmo e uma composição farmacêutica contendo o composto são fornecidos. o composto ou os sais, solvatos ou hidratos farmaceuticamente aceitáveis do mesmo e a composição farmacêutica contendo o composto podem ser usados para tratar cânceres induzidos por mutação de idh1.
BR112018069504-1A 2016-03-22 2017-03-22 Composto de sultam, uso do mesmo para tratar cânceres induzidos por mutação de idh1 e composição farmacêutica compreendendo dito composto BR112018069504B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610165138 2016-03-22
CN201610165138.6 2016-03-22
PCT/CN2017/077612 WO2017162157A1 (zh) 2016-03-22 2017-03-22 内磺酰胺化合物及其使用方法

Publications (2)

Publication Number Publication Date
BR112018069504A2 true BR112018069504A2 (pt) 2019-01-29
BR112018069504B1 BR112018069504B1 (pt) 2023-12-26

Family

ID=59899279

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069504-1A BR112018069504B1 (pt) 2016-03-22 2017-03-22 Composto de sultam, uso do mesmo para tratar cânceres induzidos por mutação de idh1 e composição farmacêutica compreendendo dito composto

Country Status (15)

Country Link
US (1) US11111240B2 (pt)
EP (1) EP3434671B1 (pt)
JP (1) JP6880166B2 (pt)
KR (1) KR102389985B1 (pt)
CN (2) CN113666922A (pt)
AU (1) AU2017239318B2 (pt)
BR (1) BR112018069504B1 (pt)
CA (1) CA3018649A1 (pt)
DK (1) DK3434671T5 (pt)
ES (1) ES2842448T3 (pt)
PT (1) PT3434671T (pt)
RU (1) RU2741915C9 (pt)
TW (1) TWI729094B (pt)
WO (1) WO2017162157A1 (pt)
ZA (1) ZA201806379B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3076405A1 (en) * 2017-09-22 2019-03-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline sulfamide compound
US20220324838A1 (en) * 2019-08-09 2022-10-13 Alembic Pharmaceuticals Limited An Improved Process Of Preparation Of Ivosidenib
WO2023226964A1 (en) * 2022-05-26 2023-11-30 Danatlas Pharmaceuticals Co., Ltd. Heterocyclic derivatives, compositions and uses thereof
WO2024131727A1 (zh) * 2022-12-19 2024-06-27 正大天晴药业集团股份有限公司 一种内磺酰胺化合物治疗胆道癌的用途
WO2024205311A1 (en) * 2023-03-31 2024-10-03 Avelos Therapeutics Inc. Substituted sultam compound derivatives and their pharmaceutical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100455899B1 (ko) * 2000-10-20 2004-11-08 주식회사 티지 바이오텍 이소시트릭산 탈수소화 효소 및 그의 유전자 그리고 이효소의 활성 및 그 유전자의 발현을 저해하는 비만,고지혈증, 지방간 등을 포함하는 대사성 질환 치료제의 선별 방법
JP6081354B2 (ja) * 2010-07-16 2017-02-15 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性組成物およびそれらの使用方法
MX350432B (es) * 2012-01-19 2017-09-06 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de empleo.
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
RU2741915C9 (ru) 2021-03-31
PT3434671T (pt) 2020-12-24
CN109071471B (zh) 2021-05-07
ES2842448T3 (es) 2021-07-14
RU2741915C2 (ru) 2021-01-29
CN109071471A (zh) 2018-12-21
RU2018136487A (ru) 2020-04-22
TWI729094B (zh) 2021-06-01
JP6880166B2 (ja) 2021-06-02
AU2017239318A1 (en) 2018-10-18
DK3434671T3 (da) 2021-01-25
JP2019513819A (ja) 2019-05-30
US20210047314A1 (en) 2021-02-18
WO2017162157A1 (zh) 2017-09-28
TW201736354A (zh) 2017-10-16
ZA201806379B (en) 2021-03-31
CA3018649A1 (en) 2017-09-28
CN113666922A (zh) 2021-11-19
AU2017239318B2 (en) 2020-08-20
EP3434671A4 (en) 2019-08-14
EP3434671A1 (en) 2019-01-30
EP3434671B1 (en) 2020-10-21
BR112018069504B1 (pt) 2023-12-26
KR20180128935A (ko) 2018-12-04
KR102389985B1 (ko) 2022-04-22
RU2018136487A3 (pt) 2020-04-24
US11111240B2 (en) 2021-09-07
DK3434671T5 (da) 2021-03-29

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
BR112018070859A2 (pt) degradantes da proteína de bet
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
BR112018069504A2 (pt) composto de sultam e método de aplicação do mesmo
PH12018501226A1 (en) Methods for treating huntingtons disease
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112019001666A2 (pt) n-(fenilsulfonil)benzamidas e compostos relacionados como inibidores de bcl-2
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
CO2017005742A2 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
BR112016028814A2 (pt) ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo?
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2017, OBSERVADAS AS CONDICOES LEGAIS